Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

571 articles

Research Review

Showing 1–3 of 3 articles · Keyword: magnetic nanoparticles Clear keyword

Beilstein journal of nanotechnology2026ReviewDrug Delivery

1. Artificial intelligence and machine learning for magnetic nanoparticles and nanocarriers in cancer imaging, drug delivery, and magnetic control: a systematic review

Yao Y, Nafo W

We reviewed artificial intelligence and machine learning in magnetic resonance imaging-visible magnetic nanoparticles, nanocarriers, and systems for imaging, drug delivery, hyperthermia, targeting, transport, and control. Using "preferred reporting items for systematic reviews and meta-analyses (PRISMA) 2020"…

Read the article

Frontiers in Immunology2021ReviewNon-viral Gene Delivery

2. Nanoparticles for Enhanced Adoptive T Cell Therapies and Future Perspectives for CNS Tumors

Balakrishnan Pb, Sweeney Ee.

Adoptive T cell therapy has revolutionized treatment of some hematologic malignancies but remains limited in solid tumours—especially central nervous system (CNS) tumours—by poor intratumoral delivery across anatomical barriers, suboptimal T cell specificity or activation, and intratumoral T cell dysfunction caused…

Read the article

ACS Applied Materials & Interfaces2020ResearchNon-viral Gene Delivery

3. Cationic Nanoparticle-Mediated Activation of Natural Killer Cells for Effective Cancer Immunotherapy

Kwang-Soo Kim, Jun-Hyeok Han, Seung Hee Choi, Hae-Yun Jung, Joo Dong Park, Hee-Jung An, Seong-Eun Kim, Dong-Hyun Kim, Junsang Doh, Dong Keun Han, Ik-Hwan Kim, Wooram Park, Kyung-Soon Park

Natural killer (NK) cells are promising for cancer immunotherapy due to their lower risk of cytokine storm and graft-versus-host disease compared to T cell therapies. However, existing NK cell activation strategies—genetic engineering and cytokine treatment—are inefficient, expensive, and involve complex processing…

Read the article

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.